Effect of GnRH agonist before IVF on outcomes in infertile endometriosis patients: a randomized controlled trial

Rodríguez-Tárrega, Elisabet; Monzó, Ana; Quiroga, Ramiro; Polo-Sánchez, Patrocinio; Fernández-Colom, Pedro J.; Monterde-Estrada, Mercedes; Novella-Maestre, Edurne; Pellicer, A.

doi:10.1016/j.rbmo.2020.06.020

Cited by 21 publications

(30 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although many studies have suggested that administrating GnRH agonists is beneficial for patients with adenomyosis in terms of improving reproductive outcomes of IVF-ET, our study did not demonstrate any advantages for the addition of GnRH agonists based on the hormone replacement therapy cycle. Similar negative findings were reported in endometriosis patients [10][11][12] . In addition, Movahedi et al performed a study in which endometrial preparation for FET using GnRH agonists appeared to be as effective as FET without these agonists 27 .…”

Section: Discussionsupporting

confidence: 89%

Effects of artificial cycles with and without gonadotropin-releasing hormone agonist pretreatment on frozen embryo transfer outcomes in patients with adenomyosis

Zhao

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Gonadotropin-releasing hormone agonist (GnRH-a) is generally added to the improve pregnancy outcomes of hormone replacement therapy cycles among patients with adenomyosis. We aimed to investigate whether adding GnRH-a can result in better pregnancy outcomes. This retrospective analysis included 341 patients with adenomyosis who underwent frozen embryo transfer (FET) after in vitro fertilization (IVF). The control group was treated only with hormone replacement therapy cycles to prepare the endometrium, and GnRH-a was added to the study group before hormone administration to adjust the menstruation cycle. Based on the similar baseline values and embryological data, there was no significant difference in the clinical pregnancy rates (40.63% vs. 42.54%, P = 0.72) and live birth rates (23.75% vs. 23.75%, P = 0.74) of the control and study groups. Other secondary outcomes, including the rates of clinical miscarriage, ectopic pregnancy, preterm birth and term birth, were not significantly different between the two groups. Compared with the hormone replacement therapy cycle alone, GnRH-a downregulation based on a hormone replacement therapy cycle may not increase the rate of clinical pregnancy or live birth of IVF-ET with FET among infertile patients with adenomyosis.

show abstract

Section: Discussionsupporting

confidence: 89%

Effects of artificial cycles with and without gonadotropin-releasing hormone agonist pretreatment on frozen embryo transfer outcomes in patients with adenomyosis

Zhao

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…More severe disease predicted lower follicular testosterone in another study (Pellicer et al, 1998 ). Following a period of gonadotropin suppression prior to in vitro fertilization (IVF), women with endometriosis showed reduced follicular testosterone relative to unaffected women (Rodríguez‐Tárrega et al, 2020 ). Reduced testosterone, or hypoandrogenemia, is characteristic of chronic inflammatory diseases—a diverse range of conditions that involve long‐term immune activation—as testosterone generally promotes energy storage and thus inhibits metabolically costly inflammation (Straub, 2014 ).…”

Section: Resultsmentioning

confidence: 99%

Endometriosis and polycystic ovary syndrome are diametric disorders

Dinsdale

Crespi

2021

Evolutionary Applications

View full text Add to dashboard Cite

Evolutionary and comparative approaches can yield novel insights into human adaptation and disease. Endometriosis and polycystic ovary syndrome (PCOS) each affect up to 10% of women and significantly reduce the health, fertility, and quality of life of those affected. PCOS and endometriosis have yet to be considered as related to one another, although both conditions involve alterations to prenatal testosterone levels and atypical functioning of the hypothalamic-pituitary-gonadal (HPG) axis. Here, we propose and evaluate the novel hypothesis that endometriosis and PCOS represent

show abstract

“…Although many studies thought that administrating GnRH agonists was very bene cial for patients of adenomyosis in improving reproductive outcomes of IVF-ET, our study did not demonstrate advantages of adding GnRH agonists based on hormone replacement therapy cycle. Similiar negative conclusions were also shown in endometriosis [10][11][12]. In addition, Movahedi S et al did a study that Endometrial preparation for FET using GnRH agonists appeared to be as effective as FET without administrating these agonists [26].…”

Section: Discussionmentioning

confidence: 94%

“…Another study found only fertilization rates but not clinical pregnancy rates involving fresh and frozen embryo transfer(FET) bene ted from GnRH-a for women with endometriosis [10]. There were also two studies which suggested GnRH-a down-regulation did not work well in patients of endometriosis undergoing IVF [11][12].…”

Section: Introductionmentioning

confidence: 99%

Effects of artificial cycles with and without gonadotropin-releasing hormone agonist pretreatment on frozen embryo transfer outcomes in patients with adenomyosis

Zhao

et al. 2021

Preprint

View full text Add to dashboard Cite

Gonadotropin-releasing hormone agonist(GnRH-a) is generally added to improve pregnancy outcomes of adenomyosis based hormone replacement therapy cycle. Our objective in this study is to investigate whether adding GnRH-a can obtain better pregnancy outcomes. In this retrospective analysis, a total of 341 patients with adenomyosis complicated in vitro fertilization-embryo transfer(IVF-ET) of the frozen embryo transfer (FET). The control group was only treated by hormone replacement therapy cycles to prepare emdometrium, and the study group was added GnRH-a before using hormone to adjust menstruation period. Based on the similar baseline values and embryological data, there was no significantly difference about their clinical pregnancy rates (40.63% vs 42.54%, P=0.72) and live birth rates (23.75% vs 23.75%, P=0.74) between the control group and the study group. Other secondary outcomes including clinical miscarriage rates, ectopic pregnancy rates, preterm pregnancy rates and term pregnancy rates did not show significant difference between the two groups. Compared with using hormone replacement therapy cycle alone, GnRH-a down-regulation based on hormone replacement therapy cycle may not increase the rates of clinical pregnancy and live birth rates in IVF-ET of FET for infertile patients with adenomyosis.

show abstract

Effect of GnRH agonist before IVF on outcomes in infertile endometriosis patients: a randomized controlled trial

Cited by 21 publications

References 34 publications

Effects of artificial cycles with and without gonadotropin-releasing hormone agonist pretreatment on frozen embryo transfer outcomes in patients with adenomyosis

Effects of artificial cycles with and without gonadotropin-releasing hormone agonist pretreatment on frozen embryo transfer outcomes in patients with adenomyosis

Endometriosis and polycystic ovary syndrome are diametric disorders

Effects of artificial cycles with and without gonadotropin-releasing hormone agonist pretreatment on frozen embryo transfer outcomes in patients with adenomyosis

Contact Info

Product

Resources

About